As part of Healthcare Innovation’s Advancing Digital Healthcare Delivery, a monthly digital health virtual series with innovators who are transforming healthcare, Rajan Wadhawan, M.D., neonatologist and senior executive officer of AdventHealth for Children and AdventHealth for Women, candidly discussed the clinical challenges of rare diseases and how a new board for the state of Florida is working to improve health outcomes for patients living with these diseases.
“Rare diseases are usually chronic and involve multiple systems, and almost all of these conditions have a genetic cause, which means they are manifesting in infants,” said Wadhawan. Because of these complexities, they are difficult to diagnose and manage, often causing a delay in care.
“Diagnosing a rare disease can take four to five years and oftentimes it includes an earlier misdiagnosis,” he said.
While rare diseases are classified as those that affect less than 200,000 people in the U.S., there are more than 7,000 different types of rare diseases – and each present with their own nuanced conditions and symptoms. All of these combined impacts an immense number of people: nearly 1 in 10 Americans are estimated to be living with rare diseases.
“The knowledge base for every condition is so vast, it is not possible for an average practicing physician to know everything about every rare disease,” Wadhawan said.
During his four-year term on Florida’s newly established Rare Disease Advisory Council (RDAC), Wadhawan will provide his expertise and personal perspective to encourage potential policy changes to make it easier for physicians and patients. This could include developing an online repository of searchable information to improve the diagnosis process and a consortium within the state or region to conduct rare disease research.
“Just like anything in life, there is so much that needs to be done that it can be overwhelming and daunting, but you have to start somewhere,” Wadhawan concludes. “We cannot be frozen by or paralyzed by the enormity of a challenge. If we first examine the areas where we can have the most impact, within the areas where we are experts, we can take it from there.”
As one of 20 representatives on Florida’s RDAC, Wadhawan and his colleagues are working to improve health outcomes for those with a rare disease and making recommendations to state leaders on critical issues, including the need for increased awareness, diagnostic tools and access to affordable treatments and cures.
12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
News
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
News
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
News
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
News
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
News
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
News
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
News
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
News
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
News
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
News
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
News
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...